Absorption enhancement of poorly absorbed hydrophilic compounds from various mucosal sites by combination of mucolytic agent and non-ionic surfactant

被引:14
作者
Takatsuka, Shinya
Morita, Takahiro
Horikiri, Yuji
Yamahara, Hiroshi
Saji, Hideo
机构
[1] Tanabe Seiyaku Co Ltd, CMC Res Labs, Dept Pharmaceut Technol, Yodogawa Ku, Osaka 5328505, Japan
[2] Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Patho Funct Bioanal, Kyoto 6068501, Japan
关键词
mucolytic agent; non-ionic surfactant; combination; mucosal; poorly absorbed hydrophilic compounds;
D O I
10.1016/j.ijpharm.2007.01.027
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Absorption enhancement of poorly absorbed hydrophilic compounds from various mucosal sites by co-administration of a mucolytic agent and a non-ionic surfactant was examined in rats. Fluorescein isothiocyanate-labeled dextran with average molecular weight of ca. 4.4 kDa (FD-4), and salmon calcitonin (SCT) were used as model compounds. N-acetylcysteine (NAC) and p-t-octyl phenol polyoxyethylene-9.5 (Triton X (R)-100, TX- 100) were selected as a mucolytic agent and a non-ionic surfactant, respectively. Dosing solutions containing these agents were administered into various mucosal sites including the nose, the lung and the large intestine, and the bioavailabilities were determined. The combination of 5% NAC and 5% TX-100 significantly enhanced the nasal, the pulmonary and the large intestinal absorption of FD-4 compared to the control, and the enhancement ratios relative to the control were 7.2-, 2.8- and 4.5-fold, respectively. The different enhancement ratio among the administration sites explored indicates that the absorption enhancing effect of the combination of NAC and TX-100 is site-dependent. This combination also improved the nasal and the pulmonary absorption of SCT, and the enhancement ratios relative to the control were 6.1- and 8.1-fold, respectively. All these results suggest that the combination strategy of a mucolytic agent and a non-ionic surfactant may be widely applicable to various mucosal deliveries of poorly absorbed hydrophilic compounds. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:87 / 93
页数:7
相关论文
共 23 条
  • [1] Agu RU, 2001, RESP RES, V2, P198
  • [2] ATUMA C, 2001, LIVER PHYSL, V280, pG922
  • [3] DRUG-DELIVERY VIA THE RESPIRATORY-TRACT
    BYRON, PR
    PATTON, JS
    [J]. JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 1994, 7 (01): : 49 - 75
  • [4] Physiology of the colorectal barrier
    Edwards, C
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 1997, 28 (02) : 173 - 190
  • [5] ABSORPTION OF SACCHARIDES AND UREA FROM RAT LUNG
    ENNA, SJ
    SCHANKER, LS
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1972, 222 (02): : 409 - &
  • [6] Oral delivery of peptide drugs -: Barriers and developments
    Hamman, JH
    Enslin, GM
    Kotzé, AF
    [J]. BIODRUGS, 2005, 19 (03) : 165 - 177
  • [7] Haupt S, 2002, CRIT REV THER DRUG, V19, P499
  • [8] HIRAI S, 1981, INT J PHARM, V7, P317
  • [9] THE STRUCTURAL BARRIER OF ABSORPTIVE MUCOSAE - SITE DIFFERENCE OF THE PERMEABILITY OF FLUORESCEIN ISOTHIOCYANATE-LABELED DEXTRAN IN RABBITS
    HOSOYA, KI
    KUBO, H
    NATSUME, H
    SUGIBAYASHI, K
    MORIMOTO, Y
    YAMASHITA, S
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 1993, 14 (08) : 685 - 695
  • [10] Absorption enhancers in pulmonary protein delivery
    Hussain, A
    Arnold, JJ
    Khan, MA
    Ahsan, F
    [J]. JOURNAL OF CONTROLLED RELEASE, 2004, 94 (01) : 15 - 24